SciELO - Scientific Electronic Library Online

vol.45 issue1Cytotoxicity of medicinal plant extracts on the human lung carcinoma cell line A549Professional profile of the Bachelor of Pharmacy in Universidad de Oriente, Cuba author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista Cubana de Farmacia

Print version ISSN 0034-7515On-line version ISSN 1561-2988


PEREZ GUERRA, Yohani; MOLINA CUEVAS, Vivian; OYARZABAL YERA, Ambar  and  MAS FERREIRO, Rosa. Pharmacological treatment of the benign prostatic hyperplasia. Rev Cubana Farm [online]. 2011, vol.45, n.1, pp.109-126. ISSN 0034-7515.

Benign prostatic hyperplasia is a common disease in over 50 years-old men consisting in uncontrolled and benign growth of prostatic gland that leads to lower urinary tract symptoms. The etiology of benign prostatic hyperplasia is multifactoral involving the increased conversion of testosterone in dihydrotestosterone by the prostatic 5a-reductase action, which brought about events that encourage the prostate growth (static component) and the increase of the bladder and prostate smooth muscle tone (dynamic component) regulated by the a1 -adrenoceptors (ADR). The pharmacological treatment of the benign prostatic hyperplasia includes the prostatic 5a-reductase inhibitors, the a1-adrenoreceptor blockers, their combined therapy and the phytotherapy. This paper was aimed at presenting the most relevant aspects of the pharmacology of drugs used for treating the benign prostatic hyperplasia, and providing elements to analyze their efficacy, safety and tolerability. To this end, a review was made of the different drugs for the treatment of this pathology and they were grouped according to their mechanism of action. Natural products were included as lipid extracts from Serenoa repens and Pygeum africanum as well as D-004, a lipid extract from Roystonea regia fruits, with proved beneficial effects on the main etiological factors of benign prostatic hyperplasia. D-004 is a prostatic 5a-reductase inhibitor, an a1-adrenoceptor antagonist, a 5-lipooxygenase inhibitor and has antioxidant action, all of which reveals a multifactoral mechanism. The results achieved till now indicate that D-004 is a safe and well-tolerated product.

Keywords : Benign prostatic hyperplasia; lower urinary tract; 5a-reductase inhibitors; a1-adrenoceptors blockers.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License